What Transformation Has the Allergy Immunotherapy Market Undergone?
The allergy immunotherapy market has seen considerable growth due to a variety of factors.
• The market size for allergy immunotherapy has seen fast growth in the past few years. It is projected to increase from $2.88 billion in 2024 to $3.17 billion in 2025, with a compound annual growth rate (CAGR) of 10.2%. The surge in growth from the historical period can be associated with a rise in allergic disease cases, advancements in the field of immunotherapy, a heightened awareness among patients, government-led initiatives, and enhancements in research and development.
What are the Market Size and Expected Growth Rates for the Allergy Immunotherapy Market Size Evolve over the Forecast Period?
The Allergy Immunotherapy market is expected to maintain its strong growth trajectory in upcoming years.
• Soon, the allergy immunotherapy market will witness a swift expansion in its size. With a compound annual growth rate (CAGR) of 12.4%.
, it will surge to $5.07 billion by 2029. The forecasted growth can be linked to the escalating global allergy burden, supportive healthcare policies, a surge in the adoption of immunotherapy, untapped markets and regions, coupled with an increase in healthcare spending. The future trends include technological progress in treatments, a rise in allergy prevalence, increase in patient awareness and education, telemedicine and remote patient monitoring, and personalized treatment strategies.
Which Key Drivers Are Propelling The Allergy Immunotherapy Market's Growth?
The allergy immunotherapy market is anticipated to grow due to the increasing occurrence of allergic disorders. These disorders are characterized by an overactive immune response to specific antigens. When these immune responses are incorrectly targeted towards the body's intrinsic parts, it results in autoimmune diseases. For those suffering from allergic disorders like IgE-mediated allergic rhinitis and allergic asthma, which are caused by inhaled allergens such as pollens and house dust mites, allergy immunotherapy is an available option. As per data published by the Medicines and Healthcare Products Regulatory Agency (MHRA) in August 202, English hospitals recorded more than 25,000 admissions for allergies and anaphylaxis in 2022-23, which is over double the figure from the preceding two decades. Furthermore, as per a report by the Food Standards Agency in May 2024, about 6% of UK adults, or approximately 2.4 million individuals, suffer from food allergies. Consequently, the allergy immunotherapy market is being driven by this increased prevalence of allergic disorders.
What Are The Key Segments Within The Global Allergy Immunotherapy Market?
The allergy immunotherapy market covered in this report is segmented –
1) By Allergy Type: Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, Other Allergy Types
2) By Treatment: Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy, Specific Immunotherapy (SIT)
3) By Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Allergic Rhinitis: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
2) By Asthma: Allergic Asthma, Non-Allergic Asthma
3) By Food Allergy: Peanut Allergy, Tree Nut Allergy, Milk Allergy, Egg Allergy, Other Food Allergies
4) By Venom Allergy: Insect Sting Allergy, Other Venom Allergies
5) By Other Allergy Types: Allergic Conjunctivitis, Eczema, Drug Allergies, Other Environmental Allergies
Pre-Book The Allergy Immunotherapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Allergy Immunotherapy Market?
Notable enterprises functioning in the allergy immunotherapy market are driving innovation by crafting technological products, like Artificial Intelligence (AI) powered allergy component testing, to remain relevant in the landscape. This new diagnostic platform leverages AI and Component Resolved Diagnostics (CRD) to diagnose a multitude of allergies. As an illustration, Metropolis Healthcare Limited, a medical laboratory firm based in India, unveiled its AI powered allergy component testing in May 2023. Serving as a fourth-generation technology in allergy testing, it utilizes AI to provide clinicians the much needed professional support in medical decision-making. It delivers valuable insights and helps in choosing and tailoring the treatment regimen for allergic diseases. Moreover, it is equipped with the ability to forecast the success rate of immunotherapy for allergy vaccinations.
Who Are the Key Players In The Allergy Immunotherapy Market?
Major companies operating in the allergy immunotherapy market include:
• LETI Pharma
• Stallergenes Greer International AG
• Allergy Therapeutics plc
• ALK-Abelló A/S
• HAL Allergy B.V.
• DBV Technologies
• Circassia Pharmaceuticals Inc.
• Jubilant HollisterStier LLC
• Allergopharma GmbH & Co. KG
• Biomay AG
• Anergis SA
• HollisterStier Allergy
• Mylan N.V.
• Adamis Pharmaceuticals Corporation
• Desentum Oy
• WOLW Pharma Limited
• AllerGenics Inc.
• Greer Laboratories Inc.
• Aimmune Therapeutics Inc.
• Reliant Laboratories Inc.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• QIAGEN NV
• Merck & Co. Inc.
• Pfizer Inc.
• Novartis AG
• GlaxoSmithKline plc
• AstraZeneca plc
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• Endo Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
What Are The Regional Insights Into The Allergy Immunotherapy Market?
Europe was the largest region in the allergy immunotherapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the allergy immunotherapy market report during the forecast period. The regions covered in the allergy immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
